Form 4: Journey Medical Director Receives Equity Grant, Boosting Beneficial Ownership

Journey Medical Corp. Director Michael Cooper Pearce was granted 7,173 restricted stock units, increasing his beneficial ownership to 37,173 shares.

Summary

• Michael Cooper Pearce, a Director of Journey Medical Corp. (DERM), reported a change in his beneficial ownership of the company's common stock.
• On June 25, 2025, Pearce was granted 7,173 restricted stock units (RSUs) of Common Stock, with a par value of $0.0001.
• These RSUs were granted at a price of $0, indicating they are part of an equity compensation plan.
• The 7,173 restricted stock units are scheduled to vest in full on June 25, 2026.
• Following this transaction, Pearce's total beneficial ownership in Journey Medical Corp. stands at 37,173 shares, which includes other restricted stock units vesting over various time periods.

Sentiment

Score: 7

Explanation: The grant of restricted stock units to a director is a positive sign of aligning management interests with shareholder value, though it's a routine compensation event rather than a strategic announcement that would significantly alter the company's outlook.

Positives

• The grant of restricted stock units aligns the director's financial interests with those of the shareholders, incentivizing long-term performance.
• Equity compensation is a standard practice for retaining and motivating key management and board members.

Negatives

• No negative information is typically disclosed in a Form 4 filing, which primarily reports insider transactions.

Risks

• A Form 4 filing primarily reports insider transactions and does not typically disclose specific company risks.

Future Outlook

The document indicates that the granted restricted stock units will vest in full on June 25, 2026, representing a future milestone for this specific equity compensation.

Industry Context

This Form 4 filing is a routine disclosure of an insider equity transaction, common across all industries as a mechanism for executive and director compensation and alignment. It does not provide information on broader industry trends or competitive dynamics.

Related Party Transactions

• Grant of 7,173 restricted stock units to Director Michael Cooper Pearce pursuant to the Issuer's 2015 Stock Plan, as amended.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's long-term interests with those of the shareholders, potentially fostering better governance and performance.

Next Steps

• The 7,173 restricted stock units granted to Michael Cooper Pearce are scheduled to vest in full on June 25, 2026.

Key Dates

Keywords

Journey Medical Corp, DERM, Michael Cooper Pearce, Form 4, SEC filing, insider transaction, restricted stock units, RSU, director, equity grant, beneficial ownership